In addition, miR-101 improves the anti-tumor effect of sorafenib in HCC cells by targeting dual-specificity phosphatase 1 (DUSP1) and inhibiting TGF-β activation (Wei et al., 2015). The gene discussed is DUSP1; the disease is neoplasm.